Description:
Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively.
- Molecular Weight:519.56
- Boiling Point:653.7±65.0°C at 760 mmHg
- Melting Point:214-216°C
- Purity:>98%
Molecular Formula:
C23H20F3N5O2S2
Canonical SMILES:
CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F
InChI:
InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)
InChIKey:
BFSMGDJOXZAERB-UHFFFAOYSA-N
Solubility:
Soluble in DMSO, DMF
Appearance:
White to Off-white Solid
Application:
Antineoplastic Agents
Storage: Store at -20°C
Synonyms:
N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-benzenesulfonamide; Dabarefenib; GSK 2118436; Tafinlar More details are to be found
here